Mycophenolic acid
- Generic Name
- Mycophenolic acid
- Brand Names
- Myfortic
- Drug Type
- Small Molecule
- Chemical Formula
- C17H20O6
- CAS Number
- 24280-93-1
- Unique Ingredient Identifier
- HU9DX48N0T
- Background
Mycophenolic acid is a potent immunosuppressant agent that inhibits de novo purine biosynthesis. It was derived from Penicillium stoloniferum, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a calcineurin inhibitor (ciclosporin or tacroli...
- Indication
Mycophenolic acid is an antimetabolite immunosuppressant indicated for prophylaxis of organ rejection in adult patients receiving kidney transplants and in pediatric patients at least 5 years of age and older who are at least 6 months post kidney transplant. Mycophenolic acid is used in combination with cyclosporine and corticosteroids.
- Associated Conditions
- Kidney Transplant Rejection
- Associated Therapies
- -
Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid
- Conditions
- Interventions
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 2
- Registration Number
- NCT05263505
- Locations
- 🇺🇸
Barnes Jewish Hospital / Washington University in St. Louis, Saint Louis, Missouri, United States
BIVV020 (SAR445088) n Prevention and Treatment of Antibody-mediated Rejection (AMR)
- First Posted Date
- 2021-12-14
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 45
- Registration Number
- NCT05156710
- Locations
- 🇺🇸
Harvard Medical School - Massachusetts General Hospital (MGH) - Medical Practice Evaluation Center (MPEC)- Site Number : 8400007, Boston, Massachusetts, United States
🇺🇸Cedars-Sinai Medical Center- Site Number : 8400100, Los Angeles, California, United States
🇺🇸University of California Los Angeles Medical Center- Site Number : 8400103, Los Angeles, California, United States
Outcomes of Patients After Allo-HSCT With Decitabine and NAC
- First Posted Date
- 2021-06-30
- Last Posted Date
- 2021-06-30
- Target Recruit Count
- 100
- Registration Number
- NCT04945096
Evaluating the Safety of Myfortic (Mycophenolate Sodium) in Patients With Lupus Nephritis
- First Posted Date
- 2020-11-27
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 64
- Registration Number
- NCT04645589
- Locations
- 🇨🇳
Novartis Investigative Site, Tao Yuan, Taiwan
Comparison between2 Drugs in Lupus Nephritis
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- Al-Azhar University
- Target Recruit Count
- 40
- Registration Number
- NCT04424602
- Locations
- 🇪🇬
ALAzhar university, Cairo, Egypt
Treg Modulation With CD28 and IL-6 Receptor Antagonists
- Conditions
- Interventions
- First Posted Date
- 2019-08-26
- Last Posted Date
- 2024-10-09
- Target Recruit Count
- 24
- Registration Number
- NCT04066114
- Locations
- 🇺🇸
Cleveland Clinic Foundation: Transplantation, Cleveland, Ohio, United States
🇺🇸University of California San Francisco School of Medicine: Transplantation, San Francisco, California, United States
🇺🇸University of Alabama School of Medicine: Transplantation, Birmingham, Alabama, United States
Glycyrrhetinic Acid Combined With Dexamethasone in Management of Newly Diagnosed ITP
- First Posted Date
- 2019-06-26
- Last Posted Date
- 2021-06-11
- Lead Sponsor
- Shandong University
- Target Recruit Count
- 30
- Registration Number
- NCT03998982
- Locations
- 🇨🇳
Qilu hospital, Shandong University, Jinan, Shandong, China
Mycophenolate Mofetil Pharmacokinetics in Systemic Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2018-09-20
- Last Posted Date
- 2020-03-13
- Lead Sponsor
- Region Skane
- Target Recruit Count
- 35
- Registration Number
- NCT03678987
- Locations
- 🇸🇪
Reumatologi SUS Lund, Region Skåne, Lund, Sweden
Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation
- Conditions
- Interventions
- First Posted Date
- 2018-03-16
- Last Posted Date
- 2023-04-24
- Lead Sponsor
- Hospital do Rim e Hipertensão
- Target Recruit Count
- 1209
- Registration Number
- NCT03468478
- Locations
- 🇧🇷
Hospital do Rim, São Paulo, Sao Paulo, Brazil
Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal Transplantation
- Conditions
- Interventions
- First Posted Date
- 2016-11-28
- Last Posted Date
- 2020-08-10
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 1
- Registration Number
- NCT02974686
- Locations
- 🇺🇸
Washington University, Saint Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.